Viracta Therapeutics, Inc. (VIRX) Reports In-Line Q3 EPS

Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q3 EPS of ($0.27), in-line with the analyst estimate of ($0.27).

For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy
• JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight